Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chicken soup for the brain? study tests daily supplements to ward off cognitive decline

NCT ID NCT04555655

Prevention Sponsor: Brand's Suntory Asia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether taking a daily chicken extract or a peptide supplement for two years could help prevent memory and thinking problems in healthy older adults aged 55 to 75. A total of 276 participants were randomly assigned to receive one of the two supplements or a placebo. The goal was to see if these supplements could slow cognitive decline and understand how they might work in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chicken extract supplement and peptide supplement
What this could lead to
If effective, these supplements could offer a simple, daily way to help maintain memory and thinking skills in older adults.
What could go wrong
This is an early-phase study, so results are preliminary. The supplements may not work better than placebo, and any benefits might be small or not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

276 people

The number who actually took part.

Started

Dec 2020

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female at 55 - 75 years of age * Baseline cognition: * Normal cognition with feelings of cognitive decline (subjective cognitive decline) OR * Mild cognitive impairment (MCI+) with memory impairment * Agree to participate in the study and provide written informed consent Exclusion Criteria: * Inadequate visual and auditory acuity to allow neuropsychological testing * Significant cerebrovascular disease * History of allergy to chicken meat * Diagnosis of Alzheimer's disease (AD) with dementia or any other dementia * Clinical dementia rating (CDR) score of \> 0.5 at screening * Evidence of other neurological, psychiatric or physical illness that can produce cognitive deterioration per investigator's judgment * Inability or unwillingness to undergo PET scan * Current diagnosis or history of alcoholism or substance addiction * Regular use of any medication in the past 6 months that may affect cognitive functioning * Regular use of cognitive enhancing supplements in the past 6 months * Subjects with excessive blood donation or blood drawn prior to baseline * Persons with a history of cardiovascular disease or any other cardiovascular or cerebrovascular diseases which investigators deem unsuitable to participate in the clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Cognitive decline Mild cognitive impairment

Contacts and locations

Locations

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • Taipei Medical University Hospital Shuang Ho Hospital

    New Taipei City, 235, Taiwan

  • Taoyuan Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.